Promising therapies for treatment of nonalcoholic steatohepatitis

Expert Opinion on Emerging Drugs

Volumn 21, Issue 3, 2016, Pages 343-357

  Noureddin, Mazen ^a   Zhang, Alice ^a   Loomba, Rohit ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Non alcoholic fatty liver disease; non alcoholic steatohepatitis; treatment for non alcoholic fatty liver disease; treatment for non alcoholic steatohepatitis

Indexed keywords

ALPHA TOCOPHEROL; BIOLOGICAL MARKER; BMS 986036; CENICRIVIROC; ELAFIBRANOR; EMRICASAN; FIBROBLAST GROWTH FACTOR; GLUCOSE; GRMD 02; IMMUNOMODULATING AGENT; JKB 121; LIRAGLUTIDE; LOSARTAN; NIVOCASAN; OBETICHOLIC ACID; OLTIPRAZ; OMEGA 3 FATTY ACID; PENTOXIFYLLINE; PIOGLITAZONE; PROBIOTIC AGENT; S ADENOSYLMETHIONINE; SELONSERTIB; SIMTUZUMAB; SITAGLIPTIN; SOLITHROMYCIN; UNCLASSIFIED DRUG; VITAMIN D;

APOPTOSIS; CHRONIC INFLAMMATION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FATTY LIVER; GLUCOSE METABOLISM; HUMAN; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; LACTOBACILLUS; LIFESTYLE MODIFICATION; LIPID STORAGE; LIPOGENESIS; LIVER CIRRHOSIS; MICROBIOME; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; STEATOSIS; WEIGHT REDUCTION; ANIMAL; DISEASE COURSE; DRUG DESIGN; NON-ALCOHOLIC FATTY LIVER DISEASE; SEVERITY OF ILLNESS INDEX;

ANIMALS; DISEASE PROGRESSION; DRUG DESIGN; HUMANS; LIVER CIRRHOSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; SEVERITY OF ILLNESS INDEX;

EID: 84984982054     PISSN: 14728214     EISSN: 17447623     Source Type: Journal    
DOI: 10.1080/14728214.2016.1220533     Document Type: Review

References (146)

1. Z.M.Younossi, M.Stepanova, M.Afendy, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011;9:524–530.
2. V.W.Setiawan, D.O.Stram, J.Porcel, et al. Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups:the multiethnic cohort. Hepatology. 2016 Jun 15. doi:10.1002/hep.28677. [Epub ahead of print]. Available from:http://www.ncbi.nlm.nih.gov/pubmed/27301913.•• Epidemiology study in a multiethnic cohort from the US showing the NAFLD is the most common cause of CLD overall and of cirrhosis in special ethnic groups.
3. M.Charlton Nonalcoholic fatty liver disease:a review of current understanding and future impact. Clin Gastroenterol Hepatol. 2004;2:1048–1058.
4. R.Vuppalanchi, N.Chalasani. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis:selected practical issues in their evaluation and management. Hepatology. 2009;49:306–317.
5. Y.Yilmaz, Z.M.Younossi. Obesity-associated nonalcoholic fatty liver disease. Clin Liver Dis. 2014;18:19–31.
6. Review Team, D.R.LaBrecque, Z.Abbas, et al. World Gastroenterology Organisation global guidelines:nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Clin Gastroenterol. 2014;48:467–473.• The World Gastroenterology Organisation guidelines on NAFLD/NASH.
7. S.McPherson, T.Hardy, E.Henderson, et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies:implications for prognosis and clinical management. J Hepatol. 2015;62:1148–1155.
8. S.Singh, A.M.Allen, Z.Wang, et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis:a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13:643–54e1-9; quiz e39–40.
9. M.Ekstedt, L.E.Franzen, U.L.Mathiesen, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865–873.
10. C.Finelli, G.Tarantino. Is there any consensus as to what diet or lifestyle approach is the right one for NAFLD patients? J Gastrointestin Liver Dis. 2012;21:293–302.
11. N.Chalasani, Z.Younossi, J.E.Lavine, et al. The diagnosis and management of non-alcoholic fatty liver disease:practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol. 2012;107:811–826.•• The American Association for the Study of Liver Diseases guidelines on NAFLD.
12. L.A.Adams, J.F.Lymp, J.St Sauver, et al. The natural history of nonalcoholic fatty liver disease:a population-based cohort study. Gastroenterology. 2005;129:113–121.
13. S.Dam-Larsen, U.Becker, M.B.Franzmann, et al. Final results of a long-term, clinical follow-up in fatty liver patients. Scand J Gastroenterol. 2009;44:1236–1243.
14. W.Dunn, R.Xu, D.L.Wingard, et al. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol. 2008;103:2263–2271.
15. M.Stepanova, N.Rafiq, Z.M.Younossi. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease:a population-based study. Gut. 2010;59:1410–1415.
16. N.P.Chalasani, A.J.Sanyal, K.V.Kowdley, et al. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis:PIVENS trial design. Contemp Clin Trials. 2009;30:88–96.
17. E.K.Spengler, R.Loomba. Recommendations for diagnosis, referral for liver biopsy, and treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Mayo Clin Proc. 2015;90:1233–1246.• Review paper on work up and treatment for NAFLD/NASH.
18. B.A.Neuschwander-Tetri, R.Loomba, A.J.Sanyal, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT):a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385:956–965.
19. L.B.Van Wagner, S.W.Koppe, E.M.Brunt, et al. Pentoxifylline for the treatment of non-alcoholic steatohepatitis:a randomized controlled trial. Ann Hepatol. 2011;10:277–286.
20. C.O.Zein, R.Lopez, X.Fu, et al. Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis:new evidence on the potential therapeutic mechanism. Hepatology. 2012;56:1291–1299.
21. D.E.Kleiner, E.M.Brunt, M.Van Natta, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321.•• Paper on the most validated histological scoring system in NASH.
22. J.D.Browning, J.D.Horton. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest. 2004;114:147–152.
23. J.C.Cohen, J.D.Horton, H.H.Hobbs. Human fatty liver disease:old questions and new insights. Science. 2011;332:1519–1523.
24. K.Hassan, V.Bhalla, M.E.El Regal, et al. Nonalcoholic fatty liver disease:a comprehensive review of a growing epidemic. World J Gastroenterol. 2014;20:12082–12101.
25. C.Postic, J.Girard. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance:lessons from genetically engineered mice. J Clin Invest. 2008;118:829–838.
26. B.Fromenty, M.A.Robin, A.Igoudjil, et al. The ins and outs of mitochondrial dysfunction in NASH. Diabetes Metab. 2004;30:121–138.
27. N.E.Sunny, E.J.Parks, J.D.Browning, et al. Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. Cell Metab. 2011;14:804–810.
28. A.J.Sanyal, C.Campbell-Sargent, F.Mirshahi, et al. Nonalcoholic steatohepatitis:association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 2001;120:1183–1192.
29. M.Noureddin, J.M.Mato, S.C.Lu. Nonalcoholic fatty liver disease:update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine. Exp Biol Med (Maywood). 2015;240:809–820.• Review paper on the pathogenesis of NAFLD/NASH.
30. D.Cai, M.Yuan, D.F.Frantz, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med. 2005;11:183–190.
31. J.W.Haukeland, J.K.Damas, Z.Konopski, et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol. 2006;44:1167–1174.
32. J.M.Hui, A.Hodge, G.C.Farrell, et al. Beyond insulin resistance in NASH:TNF-alpha or adiponectin? Hepatology. 2004;40:46–54.
33. J.Crespo, A.Cayon, P.Fernandez-Gil, et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology. 2001;34:1158–1163.
34. M.Yuan, N.Konstantopoulos, J.Lee, et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science. 2001;293:1673–1677.
35. Y.A.Lee, M.C.Wallace, S.L.Friedman. Pathobiology of liver fibrosis:a translational success story. Gut. 2015;64:830–841.
36. K.Miura, E.Seki, H.Ohnishi, et al. Role of toll-like receptors and their downstream molecules in the development of nonalcoholic fatty liver disease. Gastroenterol Res Pract. 2010;2010:362847.
37. E.Seki, D.A.Brenner. Toll-like receptors and adaptor molecules in liver disease:update. Hepatology. 2008;48:322–335.
38. K.Cope, T.Risby, A.M.Diehl. Increased gastrointestinal ethanol production in obese mice:implications for fatty liver disease pathogenesis. Gastroenterology. 2000;119:1340–1347.
39. S.F.Solga, A.M.Diehl. Non-alcoholic fatty liver disease:lumen-liver interactions and possible role for probiotics. J Hepatol. 2003;38:681–687.
40. S.L.Friedman. Preface. Hepatic fibrosis:pathogenesis, diagnosis, and emerging therapies. Clin Liver Dis. 2008;12:xiii–xiv.
41. N.C.Henderson, J.P.Iredale. Liver fibrosis:cellular mechanisms of progression and resolution. Clin Sci (Lond). 2007;112:265–280.
42. F.Oakley, V.Teoh, A.S.G.Ching, et al. Angiotensin II activates I kappaB kinase phosphorylation of RelA at Ser 536 to promote myofibroblast survival and liver fibrosis. Gastroenterology. 2009;136(2334–2344):e1.
43. E.Albanis, S.L.Friedman. Antifibrotic agents for liver disease. Am J Transplant. 2006;6:12–19.
44. S.L.Friedman, D.C.Rockey, D.M.Bissell. Hepatic fibrosis 2006:report of the third AASLD single topic conference. Hepatology. 2007;45:242–249.
45. A.Dobrzyn, J.M.Ntambi. Stearoyl-CoA desaturase as a new drug target for obesity treatment. Obes Rev. 2005;6:169–174.
46. P.Dobrzyn, A.Dobrzyn, M.Miyazaki, et al. Stearoyl-CoA desaturase 1 deficiency increases fatty acid oxidation by activating AMP-activated protein kinase in liver. Proc Natl Acad Sci USA. 2004;101:6409–6414.
47. A.Leikin-Frenkel, I.Goldiner, D.Leikin-Gobbi, et al. Treatment of preestablished diet-induced fatty liver by oral fatty acid-bile acid conjugates in rodents. Eur J Gastroenterol Hepatol. 2008;20:1205–1213.
48. R.Safadi, F.M.Konikoff, M.Mahamid, et al. The fatty acid-bile acid conjugate aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014;12:2085–91 e1.
49. H.Li, J.Zhang, W.Jia. Fibroblast growth factor 21:a novel metabolic regulator from pharmacology to physiology. Front Med. 2013;7:25–30.
50. W.Chen, R.L.Hoo, M.Konishi, et al. Growth hormone induces hepatic production of fibroblast growth factor 21 through a mechanism dependent on lipolysis in adipocytes. J Biol Chem. 2011;286:34559–34566.
51. K.Li, L.Li, M.Yang, et al. The effects of fibroblast growth factor-21 knockdown and over-expression on its signaling pathway and glucose-lipid metabolism in vitro. Mol Cell Endocrinol. 2012;348:21–26.
52. Y.Zhang, T.Lei, J.F.Huang, et al. The link between fibroblast growth factor 21 and sterol regulatory element binding protein 1c during lipogenesis in hepatocytes. Mol Cell Endocrinol. 2011;342:41–47.
53. J.Liu, Y.Xu, Y.Hu, et al. The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy. Metabolism. 2015;64:380–390.
54. T.Coskun, H.A.Bina, M.A.Schneider, et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology. 2008;149:6018–6027.
55. Y.Li, K.Wong, A.Giles, et al. Hepatic SIRT1 attenuates hepatic steatosis and controls energy balance in mice by inducing fibroblast growth factor 21. Gastroenterology. 2014;146:539–49 e7.
56. J.Xu, D.J.Lloyd, C.Hale, et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes. 2009;58:250–259.
57. B.Staels, A.Rubenstrunk, B.Noel, et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology. 2013;58:1941–1952.
58. V.Ratziu, S.A.Harrison, S.Francque, et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology. 2016;150:1147–1159 e5.
59. C.W.Chia, J.M.Egan. Incretin-based therapies in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2008;93:3703–3716.
60. M.A.Nauck, N.Kleine, C.Orskov, et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36:741–744.
61. V.Barry-Hamilton, R.Spangler, D.Marshall, et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med. 2010;16:1009–1017.
62. D.J.Cuthbertson, A.Irwin, C.J.Gardner, et al. Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists. PLoS One. 2012;7:e50117.
63. J.Shirakawa, H.Fujii, K.Ohnuma, et al. Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes. 2011;60:1246–1257.
64. G.Svegliati-Baroni, S.Saccomanno, C.Rychlicki, et al. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int. 2011;31:1285–1297.
65. J.L.Trevaskis, P.S.Griffin, C.Wittmer, et al. Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice. Am J Physiol Gastrointest Liver Physiol. 2012;302:G762–72.
66. M.J.Armstrong, P.Gaunt, G.P.Aithal, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN):a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679–690.
67. R.Shimozono, Y.Asaoka, Y.Yoshizawa, et al. Nrf2 activators attenuate the progression of nonalcoholic steatohepatitis-related fibrosis in a dietary rat model. Mol Pharmacol. 2013;84:62–70.
68. W.Kim, J.Sung Lee, C.Kyon Lee, et al. Antisteatotic efficacy and safety of the liver X receptor alpha inhibitor, dithiolethione in patients with nonalcoholic fatty liver disease. 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); 2014 Nov 7–11; Boston, MA.
69. Y.Yilmaz, O.Yonal, O.Deyneli, et al. Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis. Acta Gastroenterol Belg. 2012;75:240–244.
70. J.Cui, L.Philo, P.Nguyen, et al. Sitagliptin vs. placebo for nonalcoholic fatty liver disease:a randomized controlled trial. J Hepatol. 2016;65(2):369–376.
71. O.Takeuchi, S.Akira. Pattern recognition receptors and inflammation. Cell. 2010;140:805–820.
72. M.Yamamoto, K.Takeda. Current views of toll-like receptor signaling pathways. Gastroenterol Res Pract. 2010;2010:240365.
73. C.J.Chen, H.Kono, D.Golenbock, et al. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat Med. 2007;13:851–856.
74. Q.Zhang, M.Raoof, Y.Chen, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature. 2010;464:104–107.
75. M.Isogawa, M.D.Robek, Y.Furuichi, et al. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol. 2005;79:7269–7272.
76. E.Seki, H.Tsutsui, H.Nakano, et al. Lipopolysaccharide-induced IL-18 secretion from murine Kupffer cells independently of myeloid differentiation factor 88 that is critically involved in induction of production of IL-12 and IL-1beta. J Immunol. 2001;166:2651–2657.
77. J.Wu, Z.Meng, M.Jiang, et al. Toll-like receptor-induced innate immune responses in non-parenchymal liver cells are cell type-specific. Immunology. 2010;129:363–374.
78. Y.H.Paik, R.F.Schwabe, R.Bataller, et al. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology. 2003;37:1043–1055.
79. E.Seki, S.De Minicis, C.H.Osterreicher, et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med. 2007;13:1324–1332.
80. A.Watanabe, A.Hashmi, D.A.Gomes, et al. Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9. Hepatology. 2007;46:1509–1518.
81. M.Cengiz, S.Ozenirler, S.Elbeg. Role of serum toll-like receptors 2 and 4 in non-alcoholic steatohepatitis and liver fibrosis. J Gastroenterol Hepatol. 2015;30:1190–1196.
82. T.Csak, A.Velayudham, I.Hritz, et al. Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice. Am J Physiol Gastrointest Liver Physiol. 2011;300:G433–41.
83. R.E.Ley, P.J.Turnbaugh, S.Klein, et al. Microbial ecology:human gut microbes associated with obesity. Nature. 2006;444:1022–1023.
84. P.J.Turnbaugh, J.I.Gordon. The core gut microbiome, energy balance and obesity. J Physiol. 2009;587:4153–4158.
85. L.Miele, V.Valenza, G.La Torre, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009;49:1877–1887.
86. A.Iacono, G.M.Raso, R.B.Canani, et al. Probiotics as an emerging therapeutic strategy to treat NAFLD:focus on molecular and biochemical mechanisms. J Nutr Biochem. 2011;22:699–711.
87. R.Aller, D.A.De Luis, O.Izaola, et al. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients:a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci. 2011;15:1090–1095.
88. M.Malaguarnera, M.Vacante, T.Antic, et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci. 2012;57:545–553.
89. T.Eslamparast, H.Poustchi, F.Zamani, et al. Synbiotic supplementation in nonalcoholic fatty liver disease:a randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr. 2014;99:535–542.
90. S.Kanoh, B.K.Rubin. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev. 2010;23:590–615.
91. Y.Kobayashi, H.Wada, C.Rossios, et al. A novel macrolide solithromycin exerts superior anti-inflammatory effect via NF-kappaB inhibition. J Pharmacol Exp Ther. 2013;345:76–84.
92. P.Fernandes, T.Hashiguchi, M.Fujii, et al. Anti-NASH effects of solithromycin in NASH-HCC mouse model. Gastroenterology. 2014;146:S–145.
93. Y.J.Jiang, A.E.Teichert, F.Fong, et al. 1alpha,25(OH)2-dihydroxyvitamin D3/VDR protects the skin from UVB-induced tumor formation by interacting with the beta-catenin pathway. J Steroid Biochem Mol Biol. 2013;136:229–232.
94. R.F.Chun, P.T.Liu, R.L.Modlin, et al. Impact of vitamin D on immune function:lessons learned from genome-wide analysis. Front Physiol. 2014;5:151.
95. B.Maestro, N.Davila, M.C.Carranza, et al. Identification of a vitamin D response element in the human insulin receptor gene promoter. J Steroid Biochem Mol Biol. 2003;84:223–230.
96. U.Zeitz, K.Weber, D.W.Soegiarto, et al. Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor. FASEB J. 2003;17:509–511.
97. M.F.Holick. Vitamin D deficiency. N Engl J Med. 2007;357:266–281.
98. A.Verstuyf, G.Carmeliet, R.Bouillon, et al. Vitamin D:a pleiotropic hormone. Kidney Int. 2010;78:140–145.
99. N.Ding, R.T.Yu, N.Subramaniam, et al. A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. Cell. 2013;153:601–613.
100. T.Nakano, Y.F.Cheng, C.Y.Lai, et al. Impact of artificial sunlight therapy on the progress of non-alcoholic fatty liver disease in rats. J Hepatol. 2011;55:415–425.
101. M.Eliades, E.Spyrou, N.Agrawal, et al. Meta-analysis:vitamin D and non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2013;38:246–254.
102. N.Sharifi, R.Amani, E.Hajiani, et al. Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial. Endocrine. 2014;47:70–80.
103. S.Karnik Pharmacological inhibition of apoptosis signal-regulating kinase 1 (ASK1) in a murine model of NASH with pre-existing disease blocks fibrosis, steatosis, and insulin resistance. The Liver Meeting 2014:American Association for the Study of Liver Diseases (AASLD); 2014 Nov 7–11; Boston, MA.
104. T.M.Stulnig. Immunomodulation by polyunsaturated fatty acids:mechanisms and effects. Int Arch Allergy Immunol. 2003;132:310–321.
105. J.Bezard, J.P.Blond, A.Bernard, et al. The metabolism and availability of essential fatty acids in animal and human tissues. Reprod Nutr Dev. 1994;34:539–568.
106. U.N.Das. Biological significance of essential fatty acids. J Assoc Physicians India. 2006;54:309–319.
107. J.R.Levy, J.N.Clore, W.Stevens. Dietary n-3 polyunsaturated fatty acids decrease hepatic triglycerides in Fischer 344 rats. Hepatology. 2004;39:608–616.
108. M.Sekiya, N.Yahagi, T.Matsuzaka, et al. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology. 2003;38:1529–1539.
109. M.Teran-Garcia, A.W.Adamson, G.Yu, et al. Polyunsaturated fatty acid suppression of fatty acid synthase (FASN):evidence for dietary modulation of NF-Y binding to the Fasn promoter by SREBP-1c. Biochem J. 2007;402:591–600.
110. S.Kersten, J.Seydoux, J.M.Peters, et al. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest. 1999;103:1489–1498.
111. T.Huang, S.Bhulaidok, Z.Cai, et al. Plasma phospholipids n-3 polyunsaturated fatty acid is associated with metabolic syndrome. Mol Nutr Food Res. 2010;54:1628–1635.
112. R.B.Alfin-Slater, S.Bernick. Changes in tissue lipids and tissue histology resulting from essential fatty acid deficiency in rats. Am J Clin Nutr. 1958;6:613–624.
113. A.Werner, R.Havinga, F.Kuipers, et al. Treatment of EFA deficiency with dietary triglycerides or phospholipids in a murine model of extrahepatic cholestasis. Am J Physiol Gastrointest Liver Physiol. 2004;286:G822–G832.
114. I.P.Alwayn, C.Andersson, B.Zauscher, et al. Omega-3 fatty acids improve hepatic steatosis in a murine model:potential implications for the marginal steatotic liver donor. Transplantation. 2005;79:606–608.
115. S.C.Lu, J.M.Mato. S-adenosylmethionine in liver health, injury, and cancer. Physiol Rev. 2012;92:1515–1542.
116. J.M.Mato, M.L.Martinez-Chantar, S.C.Lu. S-adenosylmethionine metabolism and liver disease. Ann Hepatol. 2013;12:183–189.
117. J.M.Mato, S.C.Lu. Role of S-adenosyl-L-methionine in liver health and injury. Hepatology. 2007;45:1306–1312.
118. T.Bottiglieri. S-Adenosyl-L-methionine (SAMe):from the bench to the bedside–molecular basis of a pleiotrophic molecule. Am J Clin Nutr. 2002;76:1151S–7S.
119. Z.Li, L.B.Agellon, T.M.Allen, et al. The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis. Cell Metab. 2006;3:321–331.
120. J.M.Mato, J.Camara, J.Fernandez de Paz, et al. S-adenosylmethionine in alcoholic liver cirrhosis:a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol. 1999;30:1081–1089.
121. F.Hong, H.Chou, S.L.Friedman. Significant anti-fibrotic activity of cenicriviroc, a dual CCR2/CCR5 antagonist, in a rat model of thioacetamide- induced liver fibrosis and cirrhosis. Hepatology. 2013;58:1381A–1382A.
122. E.Lefebvre, T.Hashiguchi, H.Jenkins, et al. Anti-fibrotic and anti-inflammatory activity of the dual CCR2 and CCR5 antagonist cenicriviroc in a mouse model of NASH. Hepatology. 2013;58:221A–222A.
123. S.Di Lella, V.Sundblad, J.P.Cerliani, et al. When galectins recognize glycans:from biochemistry to physiology and back again. Biochemistry. 2011;50:7842–7857.
124. R.Y.Yang, G.A.Rabinovich, F.T.Liu. Galectins:structure, function and therapeutic potential. Expert Rev Mol Med. 2008;10:e17.
125. N.C.Henderson, T.Sethi. The regulation of inflammation by galectin-3. Immunol Rev. 2009;230:160–171.
126. N.C.Henderson, A.C.Mackinnon, S.L.Farnworth, et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci USA. 2006;103:5060–5065.
127. A.C.Mackinnon, M.A.Gibbons, S.L.Farnworth, et al. Regulation of transforming growth factor-beta1-driven lung fibrosis by galectin-3. Am J Respir Crit Care Med. 2012;185:537–546.
128. S.A.Harrison, N.P.Chalasani, E.Lawitz, et al. Early phase 1 clinical trial results of GR-MD-02, a galectin-3 inhibitor, in patients having non-alcoholic steatohepatitis (NASH) with advanced fibrosis. Hepatology. 2014;60:224A–227A.
129. E.Atanasova, F.Martinova, D.Jelev, et al. Alpha-2 macroglobulin is the simplest serum biomarker for liver fibrosis and fibrogenesis in chronic hepatitis C. Medinform. 2015;2:153–164.
130. H.Yoshiji, S.Kuriyama, J.Yoshii, et al. Angiotensin-II induces the tissue inhibitor of metalloproteinases-1 through the protein kinase-C signaling pathway in rat liver fibrosis development. Hepatol Res. 2003;27:51–56.
131. J.Gaedeke, H.Peters, N.A.Noble, et al. Angiotensin II, TGF-beta and renal fibrosis. Contrib Nephrol. 2001;135:153–160.
132. A.Hirose, M.Ono, T.Saibara, et al. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology. 2007;45:1375–1381.
133. S.Yokohama, M.Yoneda, M.Haneda, et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology. 2004;40:1222–1225.
134. H.J.Moon, J.Finney, T.Ronnebaum, et al. Human lysyl oxidase-like 2. Bioorg Chem. 2014;57:231–241.
135. A.H.Talal, M.Feron-Rigodon, J.Madere, et al. Simtuzumab, an antifibrotic monoclonal antibody against lysyl oxidase-like 2 (LOXL2) enzyme, appears safe and well tolerated in patients with liver disease of diverse etiology. J Hepatol. 2013;58:S532.
136. V.Ratziu, M.Y.Sheikh, A.J.Sanyal, et al. A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology. 2012;55:419–428.
137. Q.M.Anstee, D.Concas, H.Kudo, et al. Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis. J Hepatol. 2010;53:542–550.
138. F.J.Barreyro, S.Holod, P.V.Finocchietto, et al. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. Liver Int. 2015;35:953–966.
139. M.Shiffman, B.Freilich, R.Vuppalanchi, et al. A placebo-controlled, multicenter, double-blind, randomised trial of emricasan (IDN-6556) in subjects with non-alcoholic fatty liver disease (NAFLD) and raised transaminases. International Liver Congress 2015, the 50th Annual Meeting of the European Association for the Study of the Liver (EASL); 2015 Apr 22–26; Vienna, Austria.
140. M.Noureddin, J.Lam, M.R.Peterson, et al. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology. 2013;58:1930–1940.• Study on noninvasive methods to quantify liver fat through MRI.
141. R.Loomba, T.Wolfson, B.Ang, et al. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease:a prospective study. Hepatology. 2014;60:1920–1928.• Study on noninvasive methods to quantify liver fibrosis through MRI.
142. M.Noureddin, Q.M.Anstee, R.Loomba. Review article:emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2016;43:1109–1123.
143. P.Dongiovanni, S.Petta, V.Mannisto, et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol. 2015;63:705–712.
144. K.Kargiotis, V.G.Athyros, O.Giouleme, et al. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. World J Gastroenterol. 2015;21:7860–7868.
145. M.J.Tikkanen, R.Fayyad, O.Faergeman, et al. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. Int J Cardiol. 2013;168:3846–3852.
146. V.G.Athyros, K.Tziomalos, T.D.Gossios, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study:a post-hoc analysis. Lancet. 2010;376:1916–1922.